Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 UK Stocks That May Be Trading Below Estimated Value

In This Article:

The UK stock market has recently experienced some turbulence, with the FTSE 100 and FTSE 250 indices closing lower amid weak trade data from China and global economic concerns. In such an environment, identifying stocks that may be trading below their estimated value can present opportunities for investors seeking to capitalize on potential mispricings in the market.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

Name

Current Price

Fair Value (Est)

Discount (Est)

QinetiQ Group (LSE:QQ.)

£3.972

£7.83

49.3%

Foresight Group Holdings (LSE:FSG)

£3.485

£6.51

46.5%

Informa (LSE:INF)

£7.556

£14.39

47.5%

M&C Saatchi (AIM:SAA)

£1.69

£3.13

45.9%

Duke Capital (AIM:DUKE)

£0.27

£0.54

49.7%

Itim Group (AIM:ITIM)

£0.47

£0.90

47.9%

TI Fluid Systems (LSE:TIFS)

£1.99

£3.83

48.1%

Vanquis Banking Group (LSE:VANQ)

£0.605

£1.13

46.6%

Optima Health (AIM:OPT)

£1.725

£3.35

48.5%

Crest Nicholson Holdings (LSE:CRST)

£1.635

£3.20

48.9%

Click here to see the full list of 58 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Fintel

Overview: Fintel Plc provides intermediary services and distribution channels to the retail financial services sector in the United Kingdom, with a market cap of £255.27 million.

Operations: The company generates revenue from three main segments: Research & Fintech (£25.40 million), Distribution Channels (£23.80 million), and Intermediary Services (£29.10 million).

Estimated Discount To Fair Value: 39.3%

Fintel is trading at £2.45, significantly below its estimated fair value of £4.04, indicating potential undervaluation based on cash flows. Despite a drop in net income to £5.9 million from £7.1 million last year, earnings are projected to grow substantially at 30.15% annually over the next three years, outpacing the UK market's growth rate. However, profit margins have decreased from 10.9% to 7.5%, and leadership changes may impact strategic direction with Matt Timmins becoming sole CEO by mid-2025.

AIM:FNTL Discounted Cash Flow as at Apr 2025
AIM:FNTL Discounted Cash Flow as at Apr 2025

NIOX Group

Overview: NIOX Group Plc is involved in the design, development, and commercialization of medical devices for measuring fractional exhaled nitric oxide (FeNo) globally, with a market cap of £300.08 million.

Operations: NIOX Group Plc generates revenue through the global design, development, and commercialization of medical devices used for measuring fractional exhaled nitric oxide (FeNo).